ReviewFrontiers in pharmacology2026
Stathmin in human health and diseases: from cytoskeletal dynamics to clinical implications.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stathmin, a highly conserved microtubule-destabilizing protein in eukaryotes, plays a pivotal role in regulating cytoskeletal dynamics by promoting microtubule depolymerization. This process is indispensable for fundamental biological events, including cell division, migration, differentiation, and intracellular signal transduction. This review systematically elucidates stathmin's genomic architecture, molecular functions, and mechanistic contributions under both physiological and pathological contexts. The functional output of stathmin is tightly modulated by post-translational modifications, particularly phosphorylation, as well as its protein expression levels. Aberrant stathmin expression or activity is strongly implicated in tumorigenesis, driving cancer cell proliferation, invasion, metastasis, and chemoresistance. Conversely, in non-neoplastic diseases, stathmin orchestrates skin and mucosal repair, maintains neurological function, influences pulmonary fibrosis, modulates metabolic homeostasis, and supports pregnancy maintenance through its cytoskeletal regulatory capacity. Furthermore, this study highlights stathmin's significant potential as a diagnostic biomarker and a promising therapeutic target. Finally, we propose future research directions that prioritize deciphering tissue-specific regulatory mechanisms and accelerating the translation of basic scientific discoveries into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.